Publicacións en colaboración con investigadores/as de Pfizer (United States) (6)

2022

  1. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

2016

  1. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain

    European Journal of Dermatology, Vol. 25, Núm. 5, pp. 410-417

2011

  1. Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

    Cancer Genomics and Proteomics, Vol. 8, Núm. 2, pp. 93-101

2007

  1. Impacto de la EPOC en la vida diaria de los pacientes. Resultados del estudio multicéntrico EIME

    Archivos de Bronconeumologia, Vol. 43, Núm. 2, pp. 64-72